Corpus ID: 207883398

ADN-1184 a monoaminergic ligand with 5-HT 6 / 7 receptor antagonism : pharmacological profile and potential therapeutic utility 1 Running Title : Pharmacology of the monoamine antagonist ADN-1184

  title={ADN-1184 a monoaminergic ligand with 5-HT 6 / 7 receptor antagonism : pharmacological profile and potential therapeutic utility 1 Running Title : Pharmacology of the monoamine antagonist ADN-1184},
  author={M. Kołaczkowski and P. Mierzejewski and P. Bienkowski and A. Wesołowska and -. ANewman and Tancredi},
1 Citations

Figures and Tables from this paper

Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia
This study compared eight antipsychotics in rat behavioral tests of psychosis, antidepressant-like activity, and cognitive impairment as a basis for preclinical evaluation of new drug candidates intended for potential pharmacotherapy of BPSD. Expand


Characterization of MK-801-induced behavior as a putative rat model of psychosis.
MK-801-induced behavior represents a rat excitatory amino acid hypofunction model of psychosis that appears to be of clinical relevance and may be of value in the search for new antipsychotic agents. Expand
Management of the behavioral and psychological symptoms of dementia
Clinicians should discuss the potential risks and benefits of treatment with patients and their surrogate decision makers, and must ensure a balance between side effects and tolerability compared with clinical benefit and QOL. Expand
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.
There are differences between the SGAs in their ability to induce EPS that clinicians consider warrant treatment with antimuscarinic drugs, and they might be important for individual patients and should be taken into account in drug choice. Expand
Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
It is suggested that lurasidone is superior to other antipsychotics in improving the MK-801-induced memory impairment and may be clinically useful for treating cognitive impairments in schizophrenia. Expand
Enhancement of antipsychotic-like effects by combined treatment with the α1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats
It is suggested that, in the presence of low dopamine D2 receptor occupancy, additional α1-adrenoceptor blockade might improve antipsychotic efficacy, and thereby improve the therapeutic window with regard to parkinsonism. Expand
Expression of α(1)-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT(2A) receptors.
Observations indicate that NE controls the activity of most PFC pyramidal neurons via α(1)ARs, either directly or indirectly, via GABAergic interneurons, and that atypical antipsychotics may exert a more powerful control of PFC function through the simultaneous blockade of α( 1) ARs and 5-HT(2A)Rs. Expand
Impact of safety warnings on antipsychotic prescriptions in dementia: Nothing has changed but the years and the substances
Prescription trends of antipsychotics in prevalent dementia patients in the context of official warnings imply that warnings of international drug authorities and manufacturers against adverse drug events in dementia patients receiving antipsychotic drugs did not impact overall prescription behavior. Expand
Arylosulfonamides for the treatment of CNS diseases
  • PCT Int Appl WO 2012035123
  • 2012
Lundbeck’s Lu AE58054 meets primary endpoint in large placebocontrolled clinical proof of concept study in people with Alzheimer’s disease
  • Corp. Release
  • 2012
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
In spite of the relative modest nature of its adverse effects, memantine has been shown to provide only a moderate decrease in clinical deterioration in AD and VD, and hence efforts are being undertaken in the design of new and more potent memantine-based drugs to hopefully provide greater efficacy. Expand